Back to news

Zenas BioPharma Launches The Distance Between Platform to Bring Greater Visibility to the Hidden Burden of IgG4-Related Disease

Globe Newswire•17/11/2026•07:00 ET
0

Key Highlights

  • ➤Zenas BioPharma (ZBIO) launched The Distance Between IgG4-RD education platform
  • ➤61% of patients frequently or constantly worry about progression between flares
  • ➤86% of patients said others underestimate disease impact because they look healthy
  • ➤44% of patients waited three years or more for an IgG4-RD diagnosis
  • ➤Zenas surveyed 70 patients and 61 physicians in the United States

Expert Statements

John Stone, MD, MPH, Executive Chairman of the IgG4ward! Foundation

“IgG4-RD is a chronic and unpredictable disease that can affect multiple organs. For many patients, the uncertain time between flares creates anxiety that extends beyond periods of active disease”

John Stone, MD, MPH, Executive Chairman of the IgG4ward! Foundation

“Bringing those experiences into focus alongside clinical perspectives teaches physicians something about the longitudinal management of IgG4-RD that they might not otherwise appreciate. Furthermore, creating that awareness among doctors facilitates more meaningful conversations between patients and clinicians about managing IgG4-RD over time.”

Lonnie Moulder, Founder and Chief Executive Officer at Zenas

“At Zenas, we believe that advancing care begins with understanding the full experience of living with this disease”

Lonnie Moulder, Founder and Chief Executive Officer at Zenas

“These findings reinforce that there is more to IgG4-RD than what is visible or captured during a clinical visit. Through The Distance Between platform, we hope to elevate patient perspectives, encourage more meaningful conversations, and contribute to a deeper understanding of this complex, chronic disease.”

- New patient and physician surveys reveal differing perspectives on disease burden, treatment goals, and long-term management -

WALTHAM, Mass., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmune and inflammatory diseases, today announced The Distance Between platform and new findings from Zenas-sponsored patient and healthcare professional (HCP) surveys conducted to better understand the lived experience of people with IgG4-related disease (IgG4-RD). The findings reveal important differences in how people living with IgG4-RD and healthcare professionals perceive the burden of this rare and chronic immune-mediated disease, including its impact on daily life, emotional well-being, and long-term disease management. These insights helped inform The Distance Between, a new community-focused educational platform designed to elevate lived experiences, deepen understanding of IgG4-RD, and encourage more meaningful conversations between people living with IgG4-RD and their care teams.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in